May 12 2004
Bentley Pharmaceuticals, Inc. (AMEX: BNT), a specialty pharmaceutical company focused on advanced drug-delivery technologies, which also manufactures and markets generic and branded products in Europe, announced today that it has applied to list its common stock on the New York Stock Exchange (NYSE). The Company anticipates that its common stock will begin trading on the NYSE on Wednesday, May 12, 2004, under its current ticker symbol, “BNT.” Bentley’s common stock will continue to trade on the American Stock Exchange until that date.
James R. Murphy, Bentley’s President and CEO, commented, “We look forward to continuing our growth and development on the NYSE, which will assist us in achieving our goal of providing long-term value to our shareholders. We are also honored to be associated with so many other quality companies with which we share common beliefs and goals including: providing value to our shareholders; establishing a global market presence; building a strong financial position; and continuing to comply with sound business practices. We believe that our listing on the NYSE will improve our visibility in the global investment community, the world’s largest global equities market, and give us access to a broader investor base,” concluded Mr. Murphy. “We are privileged to welcome Bentley Pharmaceuticals to our family of NYSE-listed companies,” said NYSE President and co-COO Catherine R. Kinney. “We look forward to building a partnership with Bentley Pharmaceuticals and its investors.”
Lancet Commission predicts sharp increase in global prostate cancer cases